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Abstract
Retroviral insertion into a host genome is a powerful tool not only for the discovery of cancer
genes, but also for the discovery of potential oncogenic noncoding RNAs. In a large-scale mouse T
lymphocyte tumor screen we found a high density of integrations upstream of the mir-106a
microRNA cistron. In tumors containing an integration, the primary transcript encoding the mir-
106a cistron was overexpressed five to 20-fold compared with that of control tumors;
concomitantly, the mature mir-106a and mir-363 microRNAs were highly overexpressed as well.
These findings suggest the mir-106a cistron plays an important role in T cell tumorigenesis.
Findings
Retroviral insertions into the genome of a host can induce
tumor formation by altering gene expression or function.
Integration of a retrovirus near a gene can induce overex-
pression of the gene through the viral promoter or
enhancer, while insertion of a retrovirus into a gene can
cause both activation and inactivation. If the affected
genes are proto-oncogenes or tumor suppressor genes, the
insertion events may lead to tumor formation [1]. Conse-
quently, retroviral mutagenesis has been used to search
entire genomes for genes involved in cancer development
[2-4], including oncogenic microRNAs (miRNAs) [5].
MiRNAs are short (~22 bp) noncoding RNAs that are
implicated in gene regulation and cancer [6-10]. In a
large-scale retroviral insertion mutagenesis screen, we
used the murine leukemia virus (MLV) strain SL3-3,
which causes T lymphomas [11], and identified several
miRNAs that are potentially involved in tumorigenesis.
We previously demonstrated that a group of these retrovi-
ral insertions induces overexpression of the oncogenic
mmu-mir-17 miRNA cistron in mouse tumors [5]. Here
we build on our validation of the retrovirus insertional
mutagenesis method to identify oncogenic miRNA and
present another potentially oncogenic miRNA cistron,
mmu-mir-106a. In this screen, male BALB/c mice were
treated with ethyl-nitroso-urea (ENU) and bred to normal
female mice. ENU treatment was conducted to increase
the recovery of tumor suppressors in the F1 progeny
through mutagenesis of the paternal allele. Newborn off-
spring mice were then injected with MLV strain SL3-3.
After becoming moribund due to tumor development,
mice were euthanized and thymus and spleen tissues were
collected and stored at -80°C. Locations of the SL3-3 pro-
virus integration sites were identified as previously
described using a splinkerette based PCR method [3] that
amplifies genomic DNA flanking the 5' LTR of the virus.
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We identified 6234 integration sites in 2199 tumors; of
these tumors, 76 sites were located on chromosome X
upstream of a miRNA cluster containing mmu-mir-106a,
mmu-mir-20b, mmu-mir-19b-2, mmu-mir-92-2, and
mmu-mir-363. The locations of the integrations ranged
from 1.5 kb to 22 kb upstream of the miRNA cluster (Fig.
1), with proviral inserts in both sense and anti-sense ori-
entations with respect to the primary RNA transcript
encoding the miRNA cistron. The Mouse Retroviral
Tagged Cancer Gene Database [12], which compiles retro-
viral insertions into the genomic DNA from various non-
T cell derived mouse tumors, also lists 10 integrations
located upstream of the mmu-mir-106a cluster. Further-
more, Hwang et al. found that EST AI464896, which maps
to the same location as mmu-mir-363, was overexpressed
in tumors with proviral MLV integrations into this region
[13]. The radiation leukemia virus (RadLV) also fre-
quently integrates at this locus and a group of five differ-
entially spliced noncoding RNAs known as Kis2
(GenBank Accession numbers AY940614-AY940618) are
overexpressed in these tumors [14]. Because the Kis2 tran-
scripts lie directly upstream of the mir-106a miRNA clus-
ter (mmu-mir-106a overlaps these transcripts by four
bases), they likely are part of the primary transcripts con-
taining the miRNA cluster.
To determine whether the retroviral integrations in this
region affected the expression of the mir-106a cistron, we
used quantitative PCR (qPCR) to measure expression lev-
els of the primary transcript (Kis2) and the mature miR-
NAs (mmu-mir-106a and mmu-mir-363) in tumors
containing mir-106a cistron integrations as well as in con-
trol tumors lacking such integrations. To measure primary
transcript (Kis2) expression levels, a probe and primer set
was designed to AY940616, which is a common exon to
three of the alternatively spliced forms of Kis2. The probe
and primers for AY940616 were as follows: 5'-TGTGTC-
CCTGAAGTTTATTGGTGT-3', 5'-GGGTCACGAGCTC-
CCTCC-3', and 5'-[6-FAM]-
CCCCCATCAACACAAACATTCCATCA-[3BHQ1]-3'. MiR-
NAs and low molecular weight RNAs were isolated from
frozen mouse tumor tissue using the Purelink miRNA Iso-
lation Kit (Invitrogen). Large fraction RNAs were then
purified by eluting the high molecular weight RNA bound
to the first column (used for the miRNA purification).
cDNA was generated from total RNA by reverse transcrip-
tion with random hexamers using the SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen). qPCR
runs were conducted on the MX3000P (Stratagene). All
qPCR reactions were run in triplicate. As controls, tumors
not containing integrations near the mmu-mir-106a-363
cluster were also assayed. Beta-actin was used as the
endogenous reference gene (Mouse ACTB 20× VIC-MGB
probe set, Applied Biosystems) and control tumor 1 was
used as the calibrator sample in the calculation of 2-∆∆Ct
values (relative expression). All relative expression values
were normalized such that the average of the tumor con-
trols was set to 1.
Representative tumors with integration sites spanning the
upstream region of mir-106a were measured for expres-
sion of the miRNA primary transcript (Fig. 1 and Table 1).
In 16 of the 21 tumors assayed, expression of AY940616
was elevated five to 20 fold as compared to the average
expression of tumors with no integrations at this locus
(Fig. 2A). This confirms the previous report that proviral
integrations in this region can increase expression of the
Kis2 locus [14].
The mature species of mmu-mir-106a and mmu-mir-363
were then measured by RT-qPCR using a stem-loop RT
primer specific for each miRNA [15]. Accordingly, 50 ng
of each tumor miRNA preparation was reverse transcribed
with the SuperScript First-Strand Synthesis System for RT-
PCR using the following stem loop RT primers (50 nM
final concentration) 5'-GTCGTATCCAGTGCAGGGTC-
CGAGGTATTCGCACTGGATACGACTACCTG-3'(mmu-
mir-106a) and 5'-GTCGTATCCAGTGCAGGGTCCGAGG-
TATTCGCACTGGATACGACTTACAG-3' (mmu-mir-363).
The reverse transcription reactions were diluted 1:200 and
5 µl of these dilutions were used in the 25 µl qPCR reac-
tions. The annealing step was 50°C for 60s. The qPCR
probes and primers were as follows: mmu-mir-106a: 5'-
CGGCAAAGTGCTAACAGT-3', 5'-GTGCAGGGTC-
CGAGGT-3', 5'- [6-FAM]- CACTGGATACGACTACCTGC-
[BHQ1]-3'; and mmu-mir-363: 5'-TGCGGATTGCACGG-
TATC-3', 5'-GTGCAGGGTCCGAGGT-3', 5'- [6-FAM]-
CACTGGATACGACTTACAGATG- [BHQ1]-3'. Synthetic
RNA oligos (IDT) were used to generate a calibration
curve for each miRNA: 5'-CAAAGUGCUAACAGUGCAG-
GUA-3' (mmu-mir-106a) and 5'-AUUGCACGGUAUC-
CAUCUGUAA-3'(mmu-mir-363). Amplification
efficiencies of the calibration curves for mmu-mir-106a
and mmu-mir-363 were respectively 67% and 69%. Con-
centrations of the mature species were calculated using the
calibration curves and then normalized by the average of
the control tumors, to calculate relative expression levels.
Fifteen tumors with integrations in this region were
assayed by qPCR for the mature species of mmu-mir-106a
and mmu-mir-363. Approximately 70% of these tumors
had increased expression levels of mmu-mir-106a by two
to six fold, and of mmu-mir-363 by four to 12 fold over
the average expression of tumors with no integrations in
this region (Fig. 2B). The mature miRNA expression differ-
ence between tumors with integrations in this region and
the tumor controls was statistically significant [p <
0.00001 (mmu-mir-106a) and p < 0.0001 (mmu-mir-
363)] by a two sample unequal variance Student's t test.
From these data we conclude that retroviral integrationsRetrovirology 2007, 4:5 http://www.retrovirology.com/content/4/1/5
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Map of integration sites upstream of the mmu-mir-106a cistron Figure 1
Map of integration sites upstream of the mmu-mir-106a cistron. A map of the SL3-3 retroviral sites upstream of the 
mir-106a cluster is displayed using the UCSC genome website browser (February 2006 version of the mm8 genome assembly). 
Insertion sites are depicted as vertical handlebars. Tumors assayed by quantitative PCR are numbered and noted in black text.
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Expression of the primary transcript and mature species of the mmu-mir-106a cistron Figure 2
Expression of the primary transcript and mature species of the mmu-mir-106a cistron. Quantitative PCR data for 
tumors with integrations upstream of the mir-106a cistron. (A) Relative expression of AY940616 in tumors containing integra-
tion sites near the mir-106a miRNA cluster. Control tumors contain integration sites at locations in the genome other than the 
mir-106a region. "N" is cDNA generated from normal mouse spleen RNA (Ambion). (B) Relative expression of the mature 
species of mmu-mir-106a and mmu-mir-363 in tumors containing integration sites near the mir-106a cistron. Tumors are num-
bered as in Figure 1.
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in the Kis2 region cause overexpression not only of the
primary RNA, but also of the mature species of the mir-
106a cluster. This, in turn, suggests that the miRNA cluster
can drive the development of T lymphomas. Although
there is a possibility that these integrations also may affect
the expression of other oncogenes and tumor suppressors
in this region, our data clearly indicates a majority of these
integrations induce the expression of the mir-106a cluster.
As the mir-106a cistron is a homolog of the oncogenic
mir-17 cistron [16], it is not unexpected that mir-106a
would also be involved tumorigenesis. Indeed, in human
solid tumors, mir-106a expression is increased in colon,
pancreas, and prostate tumors; and mir-92-2 expression is
increased in pancreas, prostate, and stomach tumors [17].
Given the sequence similarity between the mir-17 and
mir-106a cistrons, it is likely that these clusters have over-
lapping gene targets. In humans, the mir-106a cistron
contains several paralogs to members of the mir-17 cis-
tron including mir-17, mir-19b-1, and mir-92-1 [16],
which are implicated in cancer development: overexpres-
sion of the mir-17 cluster accelerates lymphoma forma-
tion from cells of mice overexpressing c-Myc [7]. The mir-
17 cluster is also overexpressed in human lung cancer
[18]. However, in breast cancer cells, mir-17-5p expres-
sion is decreased; there it acts as a translational repressor
of the oncogene AIB1 (amplified in breast cancer 1) [19],
and in this context may formally act as a tumor suppres-
sor.
It is well established that tumorigenesis is the result of
accumulating several cooperating mutations that drive
relentless proliferation and aid in metastases. Viral inser-
tional mutagenesis, though perhaps not providing all the
mutations necessary for a full-blown tumor, follows this
multistep scenario. Although in general the superinfec-
tion barrier largely prevents multiple proviral integrations
within the same cell, re-infection does happen over time.
Because it is a rare event, such cells are selected over the
others only when these integrations also give a growth
advantage. As a consequence, in general, most viral inser-
tions ("co-mutations") in a single tumor are thought to be
causative in its formation. With the caveats of potential
passenger genes and potential oligoclonality of tumors,
co-mutation analysis may be a powerful way to find coop-
erating signaling pathways in tumorigenesis.
We detected multiple insertion sites in all of the tumor
samples we assayed from the mir-106a cluster. Genes near
common co-integration sites for these tumors include
Ahi1, Evi5, and Gfi1, candidates previously appearing in
retroviral screens [12], as well as PVT1, a noncoding RNA
frequently amplified with myc [20]. A summary of all
integration sites in the assayed tumors is listed in Table 2.
Through retroviral insertion in the mouse, we have dis-
covered another potentially oncogenic microRNA cluster,
mir-106a-363. Retroviral insertion caused significant
overexpression of this microRNA cluster indicating its role
in tumor development. This study further demonstrates
the power of retrovirus insertion as a tool to discover new
oncogenic noncoding RNAs.
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Table 1: Assayed mmu-mir-106a cistron integrations
# Tumor Location Orientation
1 1759S-158-18 chrX:48988832 G-T-
2 1890S-76-1 chrX:48988834 G-T+
3 718S-68-23 chrX:48989486 G-T+
4 1786S-166-32 chrX:48989857 G-T-
5 818S-36-8 chrX:48989770 G-T+
6 553S-122-16 chrX:48990068 G-T-
7 1758S-158-17 chrX:48989877 G-T+
8 1189S-187-12 chrX:48989980 G-T+
9 3390T-128-37 chrX:48990180 G-T-
10 3412S-171-29 chrX:48990192 G-T+
11 1544S-136-23 chrX:48990391 G-T-
12 49S-41-2 chrX:48991005 G-T-
13 800S- chrX:48991024 G-T+
14 2061S-165-11 chrX:48991259 G-T-
15 462S-66C-20 chrX:48991159 G-T+
16 494S-95-4 chrX:48996521 G-T+
17 1469S-150-34 chrX:48999846 G-T+
18 195S-19-7 chrX:49000742 G-T+
19 463S-66-21 chrX:49002308 G-T+
20 1415S- chrX:49004115 G-T+
21 2057S-172-23 chrX:49005225 G-T-
Retroviral insertion site locations (February 2006 version of the 
UCSC mm8 genome assembly) are noted by the basepair located just 
before the insertion. Orientation of the retrovirus is described using 
the following nomenclature. The gene transcript (G) and retroviral tag 
(T) is directly followed by a "+" for directionality of left to right or by 
a "-" for directionality of right to left on the chromosome. If the gene 
transcript is located to the left of the retroviral tag on the 
chromosome, the notation for the gene precedes the notation for the 
tag (G ± T±). If the transcript is to the right of the retroviral tag on 
the chromosome the order is reversed (T ± G±). If the tag is located 
within the gene, by default the gene precedes the tag annotation.Retrovirology 2007, 4:5 http://www.retrovirology.com/content/4/1/5
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Table 2: Summary of integrations in tumors assayed for the mmu-mir-106a cistron
Gene located near insertion site
Tumor # Tumor Name Location Orientation Abbr/Acc Description
1 1759S-158-18 chr18:78192824 G+T+ XM_973419
1 1759S-158-18 chr7:73480330 T-G+ XM_978127.1
1 1759S-158-18 chr5:107965444 G-T- Gfi1 Growth factor independent 1
2 1890S-76-1 chr10:20756607 G+T- Ahi1 Jouberin
2 1890S-76-1 chr7:144921997 T-G- Tpcn2 Two pore segment channel 2
2 1890S-76-1 chr15:61868694 G+T+ PVT1 Plasmacytoma variant translocation 1
3 718S-68-23 chr17:29126185 G+T- Fgd2 FYVE, RhoGEF and PH domain containing 2
3 718S-68-23 chr11:5819233 G-T- Gck Glucokinase
3 718S-68-23 chr11:66037536 G-T- Gm879 Gene model 879
4 1786S-166-32 chr5:116571294 G-T- Ccdc60 Coiled-coil domain containing 60
4 1786S-166-32 chr5:107977381 T+G- Evi5 Ecotropic viral integration site 5
5 818S-36-8 chr18:5348771 G-T- Zfp438 Zinc finger protein 438
5 818S-36-8 chr5:15380286 T-G+ Cacna2d1 Calcium channel, voltage-dependent, alpha2/delta 
subunit 1
6 553S-122-16 chr5:107957997 G-T- Gfi1 Growth factor independent 1
6 553S-122-16 chr15:62006727 G+T- PVT1 Plasmacytoma variant translocation 1
7 1758S-158-17 chr5:115421225 G-T- 2410014A08Rik Hypothetical protein LOC109154
7 1758S-158-17 chr5:107968359 G-T+ Gfi1 Growth factor independent 1
7 1758S-158-17 chr17:46990647 G-T- Tbn Taube nuss
8 1189S-187-12 chr5:107970686 G-T+ Gfi1 Growth factor independent 1
8 1189S-187-12 chr9:20880975 G-T- Tyk2 Tyrosine kinase 2
8 1189S-187-12 chr15:63293889 T+G- XM_139402
8 1189S-187-12 chr19:55328465 G+T- Acsl5 Acyl-CoA synthetase long-chain family member 5
9 3390T-128-37 chr2:117124415 G-T+ Rasgrp1 RAS guanyl releasing protein 1
9 3390T-128-37 chr7:113933436 G-T+ Rras2 Related RAS viral (r-ras) oncogene homolog 2
9 3390T-128-37 chr7:113636412 G+T- Spon1 Spondin 1, (f-spondin) extracellular matrix protein
9 3390T-128-37 chr10:20761837 G+T- Ahi1 Jouberin
10 3412S-171-29 chr10:20781072 G+T- Ahi1 Jouberin
11 1544S-136-23 chr13_random:67900 G+T+ NM_175538.2 RIKEN cDNA E130304F04 gene
11 1544S-136-23 chr9:36980695 G-T+ Slc37a2 Solute carrier family 37 (glycerol-3-phosphate 
transporter), member 2
11 1544S-136-23 chr10:58965185 G-T+ NM_001033259.1 RIKEN cDNA D130073L02 gene
12 49S-41-2 chr2:72016508 G+T+ Rapgef4 Rap guanine nucleotide exchange factor (GEF) 4
12 49S-41-2 chr17:47006160 G-T- Tbn Taube nuss
13 800S- chr7:58627272 G+T- Atp10a ATPase, class V, type 10A
13 800S- chr16:94677486 G-T- Dscr3 Down syndrome critical region gene 3
14 2061S-165-11 chr14:77172712 T+G- Akap11 A kinase (PRKA) anchor protein 11
14 2061S-165-11 chr5:107977456 T+G- Evi5 Ecotropic viral integration site 5
14 2061S-165-11 chr17:29125847 G+T- Fgd2 FYVE, RhoGEF and PH domain containing 2
15 462S-66C-20 chr2:26317278 G-T+ Notch1 Notch gene homolog 1 (Drosophila)
15 462S-66C-20 chr10:20779700 G+T- Ahi1 Jouberin
15 462S-66C-20 chr12:86435291 G+T- XM_988509
16 494S-95-4 chr10:120923128 T+G- Tbk1 TANK-binding kinase 1
16 494S-95-4 chr14:121149083 G+T+ Phgdhl1 Phosphoglycerate dehydrogenase like 1
16 494S-95-4 chr1:139964759 G-T+ Ptprc Protein tyrosine phosphatase, receptor type, C
17 1469S-150-34 chr16:48708118 G+T+ LOC432823
17 1469S-150-34 chr5:107979863 T+G- Evi5 Ecotropic viral integration site 5
17 1469S-150-34 chr12:86550688 G+T+ Jundm2 Jun dimerization protein 2
18 195S-19-7 chr10:20744863 G+T- Ahi1 Jouberin
19 463S-66-21 chr4:98038839 G+T- Inadl InaD-like (Drosophila)
19 463S-66-21 chr5:107968538 G-T+ Gfi1 Growth factor independent 1
19 463S-66-21 chr17:46998042 G-T- Tbn Taube nuss
19 463S-66-21 chr1:137623944 G+T- Tnni1 Troponin I, skeletal, slow 1
20 1415S- chr15:61998664 G+T+ PVT1 Plasmacytoma variant translocation 1
20 1415S- chr14:68239584 G-T+ Slc25a37 Solute carrier family 25, member 37
20 1415S- chr14:78271471 G+T- Elf1 E74-like factor 1
21 2057S-172-23 chr15:79832811 G-T+ Pdgfb platelet derived growth factor, B polypeptide
21 2057S-172-23 chr13:52820992 T-G- Auh AU RNA binding protein/enoyl-coenzyme A hydratase
Additional retroviral insertion sites recovered from tumors containing an insertion site upstream of the mir-106a cistron. Retroviral insertion site 
locations and orientations are notated as in Table 1. Nearby genes to the insertion sites are also listed.Publish with BioMed Central    and   every 
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